

**FACSIMILE TRANSMISSION
TO THE U.S. PATENT AND TRADEMARK OFFICE**

PLEASE DELIVER TO ATTN: BOX: PG PUB

Concerning the following application:

ATTORNEY DOCKET NO.: 8654/2072

Application of:	Krissansen, et al.	Examiner:	Not Yet Assigned
Serial No.:	10/014,887		
Filed:	December 11, 2001	Group Art Unit:	1615
Entitled:	Cancer Therapy	Conf. No.:	2382

Facsimile No.: 1-703-305-8568

Number of pages including cover sheet: 64


Transmitted herewith:

1. Request for Corrected Patent Application Publication;
2. U.S. Patent Application Publication No. US 2003/0003092 marked to show the changes; and
3. Copy of original patent application filed on January 11, 2001 marked to show the changes.

CERTIFICATION

I hereby certify that the paper identified above is being facsimile transmitted to the U.S. Patent and Trademark Office, on the date indicated below.

Date: February 28, 2003


Name: David J. Dykeman
Registration No.: 46,678
Customer No.: 29933
Palmer & Dodge LLP
111 Huntington Avenue
Boston, MA 02199-7613
Tel: 617-239-0100

Atty. Docket No.: 8654/2072

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Krissansen, et al.
Serial No.: 10/014,887
Filed: December 11, 2001
Entitled: Cancer Therapy

Examiner: Not Yet Assigned

Group Art Unit: 1615

Conf. No.: 2382

CERTIFICATE OF FACSIMILE TRANSMISSION**UNDER 37 C.F.R. § 1.6d**

I hereby certify that this correspondence and any paper referred to as being enclosed are being facsimile transmitted on the date indicated above to the United States Patent and Trademark Office Fax No. (703) 305-8568

David J. Dykeman

Name of Person Mailing Paper

Signature of Person Mailing Paper

Box: PG Pub

Commissioner for Patents

Washington, D.C. 20231

TRANSMITTAL LETTER


Enclosed for filing the above-identified patent application, please find the following documents:

1. Request for Corrected Patent Application Publication;
2. U.S. Patent Application Publication No. US 2003/0003092 marked to show the changes; and
3. Copy of original patent application filed on January 11, 2001 marked to show the changes.

The Commissioner for Patents is hereby authorized to charge any additional fees or credit any overpayment in the total fees to Deposit Account No. 16-0085, Reference 8654/2072. A duplicate of this transmittal letter is enclosed for this purpose.

Date: February 28, 2003

Respectfully submitted,



Name: David J. Dykeman

Registration No.: 46,678

Customer No.: 29933

Palmer & Dodge LLP

111 Huntington Avenue

Boston, MA 02199-7613

Tel: 617-239-0100

Atty. Docket N .: 8654/2072

PATENT

#6

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Krissansen, et al.	Examiner: Not Yet Assigned
Serial No.: 10/014,887	
Filed: December 11, 2001	Group Art Unit: 1615
Titled: Cancer Therapy	Conf. No.: 2382

CERTIFICATE OF FACSIMILE TRANSMISSION**UNDER 37 C.F.R. § 1.6d**

I hereby certify that this correspondence and any paper referred to as being enclosed are being facsimile transmitted on the date indicated above to the United States Patent and Trademark Office Fax No. (703) 305-8568

David J. Dykeman

Name of Person Mailing Paper


Signature of Person Mailing Paper

Box: PG Pub
Commissioner for Patents
Washington, D.C. 20231

REQUEST FOR CORRECTED PATENT APPLICATION PUBLICATION

Sir:

Applicants request issuance of a corrected patent application publication for the above-identified patent application that published on January 2, 2003 as U.S. Patent Publication No. US 2003/0003092. Applicants believe numerous errors listed below to be material (in particular, the errors related to Table 1 on page 7 of the publication (item no. 31 below) and numerous errors omitting text (i.e., item nos. 10, 11, 25, 29, 33 below)). Thus, Applicants request the application's publication be corrected by the USPTO.

A copy of the U.S. Patent Publication No. US 2003/0003092 marked to show the changes is attached. Also, a copy of the original patent application filed on January 11, 2001 marked to show the changes is attached.

The corrected patent application publication should include the following changes:

1. Line 5 of paragraph [0005]: "if" should read "of".
2. Line 6 of paragraph [0011]: "in" should be inserted before "addition".
3. Line 4 of paragraph [0017]: "agent" should be inserted after "restricting".

Serial No.: 10/014,887

Page 2

4. Line 1 of paragraph [0018]: "a" should be inserted after "still".
5. Line 4 of paragraph [0021]: "rejected" should read "rejection".
6. Line 6 of paragraph [0021]: "B7.1," should appear immediately before "B7.2".
7. Line 5 of paragraph [0022]: the spelling of "Splenocytes" should be corrected.
8. Line 11 of paragraph [0022]: "ac" should read "activity".
9. Line 2 of paragraph [0023]: "CDS+ T" should read "CD8+ T".
10. Line 8 of paragraph [0023]: "(53-6.72 mAb); (d) CD8 and NK cells; (e) CD4, CD8, and NK cells; and (f) CD4 and CD8" is missing from immediately after "CD8".
11. Line 9 of paragraph [0040]: "R& D Systems, Abingdon, UK, human ICAM-1 can be obtained from" is missing from immediately after "from".
12. Line 1 of paragraph [0052]: "a" should read "are".
13. Line 4 of paragraph [0052]: "NHR," should be inserted after "or".
14. Line 5 of paragraph [0052]: "C1" should read "C₁".
15. Line 7 of paragraph [0052]: "R," should read "R₃".
16. Line 3 of paragraph [0055]: "HIF-1)" should read "(HIF-1)".
17. Line 4 of paragraph [0055]: "H-1" should read "HIF-1".
18. Line 4 of paragraph [0055]: "HIF-1" should read "(HIF-1".
19. Line 11 of paragraph [0056]: ";" should be inserted before "or".
20. The word "Experimental" in paragraph [0062] should be all in upper case letters as it is a heading.

Serial No.: 10/014,887

Page 3

21. The wording in paragraph [0063] should be underlined to clearly identify it as a heading.
22. Line 15 of paragraph [0068]: "boehringer" should read "Boehringer".
23. Line 16 of paragraph [0068]: "60ug" should read "60µg".
24. Line 4 of paragraph [0070]: "37C" should read as "37°C".
25. Line 9 of paragraph [0070]: "were included. After background subtraction, percentage of lysis" is missing from immediately before "was calculated".
26. Line 2 of paragraph [0071]: "Anti" should read "anti".
27. Line 13 of paragraph [0072]: "Pk136" should read "PK136".
28. Line 4 of paragraph [0077]: "with" should read "within".
29. Line 7 of paragraph [0084]: "against a challenge with 1×10^7 tumour cells (Table 1). However, mice" is missing from immediately after "mice".
30. Line 2 of paragraph [0087]: "may be in" should read "may be an".
31. Table 1 on page 7 of the publication should appear as filed in the original patent application filed on January 11, 2001. For example, the horizontal lines should be inserted in the body of Table 1 exactly as in the filed specification, the positioning of the numbers in the 4th, 10th and 12th lines of Table 1 should be corrected (i.e., moved one column to the right), and the superscript "A" in the heading of Table 1 should be corrected to be "a".
32. Line 5 of paragraph [0088]: "of" should be inserted before "antisense".
33. Line 6 of paragraph [0093]: ")P<0.05)" should read "(P>0.05)".
34. In paragraph [0113] "groeneegen" should read "Groeneegen".
35. In paragraph [0125] "5,6-dimethylxanthenone-4acetic" should read "5,6-dimethylxanthenone-4-acetic".

Serial No.: 10/014,887


Page 4

36. In paragraph [0131] There should be a "." after acid on line 5 of the paragraph.
37. On lines 4-5 of paragraph [0135] "5,6-Dimethylxanthenone-4-acetic acid" should read "5,6-Dimethylxanthenone-4-acetic acid".
38. On line 6 of paragraph [0135] "33043307" should read "3304-3307".
39. On line 3 of paragraph [0138] "(SC 347512)" should read "(NSC 347512)".

This request is being filed within 2 months of the publication date of this application, therefore Applicants believe that no fees are due.

Date: February 28, 2003

Respectfully submitted,



Name: David J. Dykeman

Registration No.: 46,678

Customer No.: 29933

Palmer & Dodge LLP

111 Huntington Avenue

Boston, MA 02199-7613

Telephone: (617) 239-0100

Telecopier: (617) 227-4420